The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

Abstract Since 1990, several techniques have been developed to photochemically inactivate pathogens in platelet concentrates, potentially leading to safer transfusion therapy. The three most common methods are amotosalen/UVA (INTERCEPT Blood System), riboflavin/UVA–UVB (MIRASOL PRT), and UVC (Theraf...

Full description

Saved in:
Bibliographic Details
Published in:Blood reviews 2014-11, Vol.28 (6), p.235-241
Main Authors: Kaiser-Guignard, Julie, Canellini, Giorgia, Lion, Niels, Abonnenc, Mélanie, Osselaer, Jean-Claude, Tissot, Jean-Daniel
Format: Article
Language:English
Subjects:
Amotosalen
Blood Platelets - cytology
Blood Platelets - drug effects
Blood Platelets - microbiology
Blood Platelets - radiation effects
Furocoumarins - pharmacology
Hematology, Oncology and Palliative Medicine
Hemovigilance
Humans
Pathogen inactivation
Pathogen reduction
Platelet concentrates
Platelet Transfusion - methods
Platelet Transfusion - standards
Platelets
Riboflavin
Riboflavin - pharmacology
Transfusion
Ultraviolet Rays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Since 1990, several techniques have been developed to photochemically inactivate pathogens in platelet concentrates, potentially leading to safer transfusion therapy. The three most common methods are amotosalen/UVA (INTERCEPT Blood System), riboflavin/UVA–UVB (MIRASOL PRT), and UVC (Theraflex-UV). We review the biology of pathogen inactivation methods, present their efficacy in reducing pathogens, discuss their impact on the functional aspects of treated platelets, and review clinical studies showing the clinical efficiency of the pathogen inactivation methods and their possible toxicity.
ISSN:0268-960X
1532-1681
DOI:10.1016/j.blre.2014.07.005